PCOS

Second Opinion Expert Announces OC FERTILITY® + OC BIOGENIX® To Join Its Panel To Provide Expert Second Opinions.

Retrieved on: 
Saturday, May 4, 2024
Patient, PCOS, PGT, Infertility, Freezing, Anesthesiology, SOE, ICSI, Fertility, Genetic testing, IVF, Embryology, MPH, DANA, OC, IUI, FACOG, Semen analysis

DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.

Key Points: 
  • DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.
  • "We are honored to join the SOE panel to provide our expertise for challenging fertility cases and excited to leverage SOE's powerful second opinion platform as another way for us to help families," said Dr. Sharon Moayeri, founder and medical director of OC Fertility® + OC Biogenix®.
  • OC Fertility® + OC Biogenix® is a leading Southern California medical practice providing the best in fertility care and advanced laboratory services.
  • OC Fertility® + OC Biogenix®'s expert team features: Board-certified specialists, fellowship-trained in reproductive endocrinology, infertility, embryology, and anesthesiology, advanced public health education & advocacy and patient-centered, trauma-informed care.

Bridging Healthcare Gaps: The Wonder Woman Collective Unveils a New Vision for Women's Health

Retrieved on: 
Friday, May 3, 2024
PCOS, Health equity, Urinary incontinence, Wonder, Infertility, Health, McKinsey & Company, Partnership, Human, Research, Pelvic floor dysfunction, Pelvic floor, Grammatical mood, Hypothyroidism, IVF, Entrepreneurship, Mental health, Patient, Work, Mother, Diagnosis, Migraine, Menopause, Quality of life, Nursing

With a shared commitment to innovation and excellence, this is the start of a foundation where future companies can join and redefine the standard of care in women's health. "With this initiative, we forge a new path in healthcare - one where comprehensive care, innovation, and patient-centricity are not just ideals, but realities. This is where the future of women's health begins." said Elizabeth Burstein, Co-Founder and CEO of Neura Health. Tina Keshani, Founder and CEO of Seven Starling adds "Women deserve specialized and tailored healthcare solutions to address their unique needs -- and no one company can do it all. "

Key Points: 
  • Five leading women's health companies, Paloma Health, Neura Health, LEVY Health, Seven Starling and Origin, have joined forces to announce The Wonder Woman Collective.
  • This strategic partnership addresses critical gaps in women's healthcare, focusing on improving healthcare outcomes, promoting health equity, reducing costs, and enhancing women's health.
  • "Addressing the Women's Health Gap is not just an option but a critical necessity.
  • "Through The Wonder Woman Collective, we are unifying diagnostic expertise and specialized care, enhancing the patient's journey and offering timely, comprehensive solutions," said Caroline Mitterdorfer, Co-Founder and CEO of LEVY Health.

Boston IVF Welcomes Dr. Josette Dawkins to its Springfield Fertility Center, Further Enhancing Access to Expert Reproductive Care in Western Massachusetts

Retrieved on: 
Monday, April 29, 2024
University, Hysterosalpingography, PCOS, Suite, REI, MD, Fertility, Rochester Regional Health, Baystate, HSG, Obstetrics, IVF, Gynaecology, University of Massachusetts, Family, Medicine, Assistant, IUI, Medical director, Semen analysis, Nursing

SPRINGFIELD, Mass., April 29, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce the addition of reproductive endocrinologist, Dr. Josette Dawkins, MD to its Springfield, MA fertility center and team.

Key Points: 
  • The addition of Dr. Josette Dawkins to Boston IVF and its fertility clinic in Springfield enriches the accessibility of timely reproductive care for individuals seeking to start a family.
  • She joins Boston IVF from Baystate Reproductive Medicine in Springfield, MA – where she served as its Medical Director.
  • "We are thrilled to extend a warm welcome to Dr. Josette Dawkins as she joins our esteemed Boston IVF team in Springfield, Massachusetts," expressed David Stern, CEO of Boston IVF.
  • "I am honored to become part of the respected team at Boston IVF," said Dr. Josette Dawkins.

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Saturday, April 27, 2024
Use, Polycystic ovary syndrome, Ovarian reserve, PCOS, WHO, Hormone, Danaher Corporation, Primary ovarian insufficiency, Health, World Health Organization, Woman, Infertility, Anti-Müllerian hormone, Health care, AMH, Fertility, Table, Intelligence, IVF, Bio-Rad Laboratories, Privacy, Thermo Fisher Scientific, Diagnosis, POC, Growth, Birth control

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.

Key Points: 
  • Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.
  • A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market.
  • "Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures"

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Saturday, April 27, 2024
Use, Polycystic ovary syndrome, Ovarian reserve, PCOS, WHO, Hormone, Danaher Corporation, Primary ovarian insufficiency, Health, World Health Organization, Woman, Infertility, Anti-Müllerian hormone, Health care, AMH, Fertility, Table, Intelligence, IVF, Bio-Rad Laboratories, Privacy, Thermo Fisher Scientific, Diagnosis, POC, Growth, Birth control

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.

Key Points: 
  • Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.
  • A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market.
  • "Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures"

Rosy Debuts New Content Focused on Menopause and Migraine Education

Retrieved on: 
Thursday, April 18, 2024
Physician, Webby, PCOS, Woman, Health, MD, Endometriosis, Webby Awards, Migraine, Female, Sensation, Patient, Diagnosis, OB, Libido, Personal lubricant, Quality of life, Menopause, Knowledge, Disability, Birth control

DALLAS, April 18, 2024 /PRNewswire-PRWeb/ -- Rosy, the Webby Award winning app-based platform that addresses common health concerns for women throughout their lifespans, announces an expanded focus beyond sexual wellness. Through its new sponsorship from Pfizer, one of the world's premier biopharmaceutical companies, Rosy will provide women in the U.S. with free evidence-based resources, rolled out in two phases. The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.

Key Points: 
  • The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.
  • When signing up for Rosy, each user takes a comprehensive Wellness Quiz, allowing Rosy to personalize an evidence-based, CBT-informed program with their unique concerns and priorities in mind.
  • While initially focused on sexual wellness, Rosy has expanded to include a wider range of women's health concerns, including endometriosis, PCOS, and more.
  • Physicians, providers, and hospital systems interested in recommending Rosy to their female patients are welcome to email [email protected] .

Beli Introduces Innovative Preconception Boost: A New Step Toward Optimizing Fertility Before Pregnancy

Retrieved on: 
Thursday, April 18, 2024
PCOS, PMS, Pregnancy, Health, Thought, Fertility, Water, Science, Nutrient, Multimedia, Ovulation, Overalls, Knowledge, Birth control

KIRKLAND, Wash., April 18, 2024 /PRNewswire-PRWeb/ -- Targeted nutrient support for Hormonal Balance, Egg Quality, Cycle Regularity and More in One Innovative Supplement

Key Points: 
  • Beli is excited to announce the launch of its latest innovation, the Beli Preconception Boost for Women.
  • Beli is excited to announce the launch of its latest innovation, the Beli Preconception Boost for Women.
  • "Beli stands at the forefront of fertility and preconception health with the launch of this supplement," added Davis.
  • The Preconception Boost for Women is now available, marking a new era in fertility and preconception care.

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, Research, A4, GC, Congenital adrenal hyperplasia, Administration, PCOS, P-value, GCS, Patient, Cash, Șaeș, Spruce, Outline, CAH, Clinical trial, Safety, Hyperandrogenism, Polycystic ovary syndrome, ULN, Research and development, Food, FDA, Pharmaceutical industry

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
  • “We are grateful to all the patients, families, study team and investigators who supported the CAHmelia-203 clinical trial,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences.
  • Non-cash stock-based compensation expense for the year ended December 31, 2023 was $4.6 million compared to $3.6 million in 2022.
  • Net Loss: Net loss for the year ended December 31, 2023 was $47.9 million compared to $46.2 million in 2022.

CCRM FERTILITY WELCOMES REGIONAL DIRECTOR OF CLINICAL REPRODUCTIVE GENETICS, DR. JASMINE ALY, TO JERSEY CITY TEAM

Retrieved on: 
Wednesday, March 27, 2024
ART, WRNMMC, Obstetrics, PCOS, Gynaecology, Obesity, Polycystic disease, Reproductive Sciences, Science, NHGRI, Genetic distance, FACOG, Genetics, COVID-19, Patient, Empathy, Medical genetics, Cooper University Hospital, Research, African Americans, USUHS, Fibroid, Reproduction, Assisted reproductive technology, IRMS, NIH, Polycystic ovary syndrome, Outline of health sciences, Reproductive endocrinology and infertility, Publication, Fertility, REI, Birth control

JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey. Dr. Aly holds the rare distinction of being a triple-specialized physician as an Obstetrician-Gynecologist, Reproductive Endocrinologist, and Medical Geneticist.

Key Points: 
  • JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey.
  • As Regional Director of Clinical Reproductive Genetics, Dr. Aly will bring her expertise to the CCRM Fertility team and aims to leverage her comprehensive fellowship training in genetics to further advance the field and better serve patients.
  • As an esteemed reproductive endocrinologist, she will utilize cutting-edge  technology and innovative scientific techniques to ensure patient success rates continue to rise.
  • "Dr. Aly's expertise in genetics is an invaluable attribute that will redefine care at CCRM | IRMS," notes CCRM Fertility CEO, Bob LaGalia.

San Diego Fertility Center, an Ivy Fertility Clinic, Hires Dr. Valerie Flores

Retrieved on: 
Wednesday, February 21, 2024
Research, Women, Baby, Maternity, Practice Management, Family, Biotechnology, General Health, Consumer, Health, Science, Fertility preservation, MD, NIH, Physician, Pain, Endometriosis, University of Southern California, Yale University, University, SDFC, PCOS, Patient, Uterus, Brown, Infertility, Medical device

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).
  • “We are thrilled that Dr. Flores will be contributing her talents to our physician team,” said Sandy Chuan, MD, medical director at San Diego Fertility Center.
  • She comes to San Diego Fertility Center from Reproductive Partners Fertility Center in San Diego, is an Assistant Professor Adjunct at Yale University’s School of Medicine.
  • “I admire San Diego Fertility Center and Ivy Fertility for leading our industry by putting compassion and collaboration first,” said Dr. Flores.